INTEGRA LIFESCIENCES HOLDINGS CORP 10-Q

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS The following table provides information about purchases by the Company during the quarter ended March 31, 2022 of equity securities that are registered by the Company pursuant to Section 12 of the Exchange Act. Subject to applicable law, share repurchases may be made from time to time in open market transactions, privately negotiated transactions including accelerated share repurchase agreements, or pursuant to instruments and plans complying with Rule 10b5-1 under the Exchange Act, among other types of transactions and arrangements. Issuer purchases of equity securities Period Total number of shares purchased by month Average price paid per share Total number of shares purchased by month as part of publicly announced repurchase programs Approximate dollar value of shares that may yet be purchased under the plans or program 01/01/22 - 01/31/22 1,477,760 64.50 1,477,760 100,000,000 02/01/22 - 02/28/22 — — — 100,000,000 03/01/22 - 03/31/22 460,250 64.50 460,250 100,000,000 1,938,010 $ 64.50 1,938,010 100,000,000 On December 7, 2020, the Board of Directors authorized the Company to repurchase up to $225.0 million of the Company’s common stock (the “repurchase program”). As part of the repurchase program, we entered into an accelerated share repurchase agreement with a bank in January 2022 to repurchase an aggregate of $125 million of our common stock (the “2022 ASR”). In January 2022, we received 1.48 million shares of Company common stock at inception of the 2022 ASR, which represented approximately 80% of the expected total shares under the 2022 ASR. In March 2022, the 2022 ASR transaction was completed, and an additional 0.46 million shares were delivered pursuant to the accelerated share repurchase agreement. The 1.9 million shares delivered in connection with the 2022 ASR were the only shares of Integra common stock we repurchased during the first quarter of 2022. See Note 11, Treasury Stock of the Notes to Consolidated Financial Statements (Part I, Item 1 of this Form 10-Q) for additional information regarding our share repurchase program and the 2022 ASR. ITEM 4. MINE SAFETY DISCLOSURES Not applicable.